Drug Profile
Biosimilar antibody therapeutic - Abzena
Latest Information Update: 28 Nov 2021
Price :
$50
*
At a glance
- Originator Abzena
- Class
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Multiple sclerosis
Most Recent Events
- 28 Nov 2021 No recent reports of development identified for research development in Multiple-sclerosis in United Kingdom (Parenteral)
- 19 Oct 2017 Abzena and UGA Biopharma enter into a partnership to develop a cell line expressing the biosimilar antibody therapeutic for Multiple Sclerosis
- 19 Oct 2017 Early research in Multiple sclerosis in United Kingdom (Parenteral)